




Physiology


Platelets, Hemostasis, and Bleeding Disorders

م.د. أحمد تركي هاني
MBChB. MSc. PhD.

Hemostasis Overview



Clotting process in a traumatized blood vessel.



Blood clotting
Positive Feedback:

Hemostasis:

All physiological processes that prevent and stop bleeding in case of blood vessel injuries.

Three Major Steps:

1. **Vascular Spasm:** Vasoconstriction at injury site

2. **Primary Hemostasis:**


- Platelet plug formation

3. **Secondary Hemostasis:**


- Coagulation cascade → Fibrin clot formation

End Result: Stable fibrin-platelet clot sealing the vessel

Platelets + Fibrin =
Clot formation




Platelet Formation (Thrombopoiesis)



Thrombopoiesis:

Production of thrombocytes (platelets) by megakaryocytes in the bone marrow.



- **Origin:** Hematopoietic stem cells → Myeloid lineage → Megakaryocytes
- **Regulation:**
- Thrombopoietin (TPO): Main regulator, produced by liver & kidneys
- **Process:**
- Megakaryocytes extend cytoplasmic processes (proplatelets) into bone marrow sinusoids
- Platelets bud off from proplatelets
- **Lifespan:** 7–10 days
- **Clearance:** By spleen and liver

Functions of Platelets

Primary Hemostasis:

- Adhesion to exposed collagen (via vWF)
- Activation and shape change
- Secretion of granules (ADP, thromboxane A₂)
- Aggregation (GpIIb/IIIa binding fibrinogen)

Support for Coagulation:

- Provide phospholipid surface for coagulation cascade

Other Roles:

- Inflammation and immune modulation
- Angiogenesis and wound healing

Coagulation Cascade

Secondary Hemostasis:

Activation (a) of Coagulation cascade via (**Extrinsic/Intrinsic**) pathway = formation of fibrin

- **Intrinsic Pathway:** Initiated by contact activation
- **Extrinsic Pathway:** Triggered by tissue factor
- **Common Pathway:** Factor X \rightarrow Xa \rightarrow Thrombin \rightarrow Fibrin
- Amplification and feedback mechanisms by thrombin

Anticoagulants (Physiological)

Endogenous Anticoagulants:

- **Antithrombin III:** Inhibits thrombin, Factor Xa
- **Protein C & S:** Inactivate Factors Va and VIIIa
- **Tissue Factor Pathway Inhibitor (TFPI):** Inhibits extrinsic pathway
- Fibrinolysis:
- **Plasminogen** → Plasmin (via tPA)
- Plasmin breaks down fibrin clot

Clinical Anticoagulants


- **Heparin**: Activates antithrombin III
- **Warfarin**: Inhibits Vitamin K-dependent factors (II, VII, IX, X)
- **tPA** (Alteplase): Clot dissolution in stroke, MI

Bleeding Disorders

- Normal platelets Count: 150,000–400,000/ μ L
- **Thrombocytopenia**: <150,000/ μ L
- Causes: bone marrow failure, autoimmune (ITP), infections, drugs
- **Thrombocytosis**: >400,000/ μ L
- Causes: myeloproliferative disorders, inflammation (reactive)


Purpura

- Definition: Purple discolorations due to small vessel bleeding
- Types:
 - Thrombocytopenic: e.g., ITP (immune thrombocytopenia purpura)
 - Non-thrombocytopenic: e.g., vascular fragility (scurvy, steroids)




Hemophilia

- Type A: Factor VIII deficiency
- Type B: Factor IX deficiency
- Inheritance: X-linked recessive



The child will have ONE of the four following combination of genes:




Hemophilia

- Clinical Features:
- Deep tissue bleeds, hemarthroses
- Lab Findings: Increased aPTT, normal PT/platelets
- Treatment: Factor replacement therapy



hemarthrosis



Ecchymosis

Summary

- Platelets are essential for primary hemostasis and coagulation support
- Hemostasis involves a cascade of tightly regulated events
- Bleeding disorders (hemophilia, purpura) arise from defects in coagulation or platelets
- Understanding mechanisms guides effective treatment